Roche’s Actemra Scores New Indication In Rare Autoimmune Disease
SSc-ILD Indication Comes With Biosimilar Competition On The Horizon
Executive Summary
The blockbuster drug is expected to see overall sales declines in the next few years, and biosimilar competition could come as soon as 2023.
You may also be interested in...
Certa Plans Pivotal Scleroderma Trial As GPCR Antagonist Hits Phase II Bullseye
Certa’s lead candidate has shown promise in a mid-stage trial for the rare but debilitating skin disorder, triggering pivotal development plans to address the high unmet need.
Coronavirus Update: At One-Year Mark, WHO Stresses Importance Of Fair Vaccine Distribution
Plus Pfizer/BioNTech report real-world data from Israel on its vaccine, while Roche’s Actemra misses Phase III endpoint in another combo study with Veklury.
Pegfilgrastim Next As Fresenius Kabi Eyes Five Biosimilars In 2025
Fresenius Kabi has drawn up a roadmap to offering five biosimilar products by 2025, with a biosimilar to Amgen’s Neulasta (pegfilgrastim) set to rival competitors in the US and Europe later this year, ahead of a biosimilar to Roche and Chugai’s Actemra/Ro-Actemra (tocilizumab).